Dr Israel Lowy, senior vice president of translational and clinical sciences in ... and vice-chair of the Trial Steering Committee, commented: “Libtayo is an important advancement for patients ...

Sanofi and Regeneron plan to file their cancer immunotherapy Libtayo (cemiplimab) in a new indication following supportive findings from a phase 2 trial in ... has shown a clinical benefit in ...

Under the terms of the agreement, Immuneering will sponsor the planned studies, while Regeneron will provide Libtayo ... in its ongoing Phase 2a clinical trials involving IMM-1-104, a treatment ...

Sensei is conducting a multi-center Phase 1/2 clinical trial to evaluate the safety ... in combination with Regeneron’s PD-1 inhibitor Libtayo ® (cemiplimab) in patients with advanced solid ...

All received solnerstotug (3 mg/kg or 15 mg/kg) with Libtayo. Eleven had not yet reached the first ... medical oncologist and Director of Clinical Research at NEXT Oncology - Dallas, and a principal ...

Therefore, Senhwa will actively pursue licensing possibilities while carefully evaluating CX-4945's potential as a monotherapy or in combination with the second-line immunotherapy Libtayo.

FibroGen said it believes that the mechanisms of action for both FG-3165 and FG-3175 have the potential to be synergistic with Libtayo, also known as cemiplimab, which could improve clinical outcomes.

This trial is particularly noteworthy as it evaluated CX-4945 monotherapy in patients who had already failed first-line HHIs. Notably, 27.3% (6 patients) had also failed second-line PD-1 inhibitors ...